In the once-daily-fixed-dose combo pills fight, GILD's next move is TAF-quad (in phase III trials) that in phase II showed a better AE (kidneys and bones) profile vs. Stribild.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.